Evidence map›Paper›PMID 35970983›Full record

ArticleNature communications2022

Regional connectivity drove bidirectional transmission of SARS-CoV-2 in the Middle East during travel restrictions.

Edyth Parker, Catelyn Anderson, Mark Zeller, Ahmad Tibi, Jennifer L Havens, Geneviève Laroche, Mehdi Benlarbi, Ardeshir Ariana, Refugio Robles-Sikisaka, Alaa Abdel Latif and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Edyth Parker *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. eparker@scripps.edu.ORCID 0000-0001-8312-1446
Catelyn Anderson *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Mark Zeller *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Ahmad TibiBiolab Diagnostic Laboratories, Amman, Jordan.
Jennifer L HavensBioinformatics and Systems Biology Graduate Program, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-3095-5900
Geneviève LarocheDepartment of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada.
Mehdi BenlarbiDepartment of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada.
Ardeshir ArianaDepartment of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada.
Refugio Robles-SikisakaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Alaa Abdel LatifDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Alexander WattsBluedot, Toronto, ON, Canada.
Abdalla AwidiCell Therapy Center, The University of Jordan, Amman, Jordan.
Saied A JaradatPrincess Haya Biotechnology Center, Jordan University of Science and Technology, Irbid, Jordan.
Karthik GangavarapuDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Karthik RameshDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Ezra KurzbanDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Nathaniel L MattesonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Alvin X HanDepartment of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.ORCID 0000-0001-6281-8498
Laura D HughesDepartment of Integrative, Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0003-1718-6676
Michelle McGrawDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Emily SpencerScripps Research Translational Institute, La Jolla, CA, USA.
Laura NicholsonScripps Research Translational Institute, La Jolla, CA, USA.ORCID 0000-0002-1761-0951
Kamran KhanBluedot, Toronto, ON, Canada.
Marc A SuchardDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-9818-479X
Joel O WertheimDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Shirlee WohlDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Marceline CôtéDepartment of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada.
Amid AbdelnourBiolab Diagnostic Laboratories, Amman, Jordan.
Kristian G AndersenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-6431-5982
Issa Abu-DayyehBiolab Diagnostic Laboratories, Amman, Jordan. i.abudayyeh@biolab.jo.ORCID 0000-0003-0224-2292

Funding

Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Scripps Translational Science InstituteUL1TR002550 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2018 to 2022
$28.9M
Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC)U01AI151378 · NIAID · RESEARCH TRIANGLE INSTITUTE · PI Gregory D Sempowski · 2020 to 2026
$14.7M
West African Emerging Infectious Disease Research Center (WA-EIDRC)U01AI151812 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ANDERSEN, KRISTIAN GRAUGAARD, GARRY, ROBERT F · 2020 to 2024
$13.2M
Automation and Evaluation of Real-Time Transmission Network-Based HIV Prevention Services in New York CityR01AI135992 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WERTHEIM, JOEL OKRENT · 2018 to 2022
$3.6M
CIHR OV3 170632NCATS NIH HHS UL1 TR002550NIAID NIH HHS R01 AI135992NIAID NIH HHS U01 AI151378NIAID NIH HHS U01 AI151812NIAID NIH HHS U19 AI135995
6 · The paper itself

Abstract

Regional connectivity and land travel have been identified as important drivers of SARS-CoV-2 transmission. However, the generalizability of this finding is understudied outside of well-sampled, highly connected regions. In this study, we investigated the relative contributions of regional and intercontinental connectivity to the source-sink dynamics of SARS-CoV-2 for Jordan and the Middle East. By integrating genomic, epidemiological and travel data we show that the source of introductions into Jordan was dynamic across 2020, shifting from intercontinental seeding in the early pandemic to more regional seeding for the travel restrictions period. We show that land travel, particularly freight transport, drove introduction risk during the travel restrictions period. High regional connectivity and land travel also drove Jordan's export risk. Our findings emphasize regional connectedness and land travel as drivers of transmission in the Middle East.

Indexed as

COVID-19SARS-CoV-2HumansMiddle EastPandemicsTravel

Identifiers

PMID35970983
PMCPMC9376901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.